OKYO Pharma Limited, (OKYO): Price and Financial Metrics


OKYO Pharma Limited, (OKYO): $2.22

-0.10 (-4.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OKYO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OKYO Stock Price Chart Interactive Chart >

Price chart for OKYO

OKYO Price/Volume Stats

Current price $2.22 52-week high $6.11
Prev. close $2.32 52-week low $1.61
Day low $2.21 Volume 3,400
Day high $2.43 Avg. volume 8,530
50-day MA $2.13 Dividend yield N/A
200-day MA $0.00 Market Cap 48.33M

OKYO Pharma Limited, (OKYO) Company Bio


OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.


OKYO Latest News Stream


Event/Time News Detail
Loading, please wait...

OKYO Latest Social Stream


Loading social stream, please wait...

View Full OKYO Social Stream

Latest OKYO News From Around the Web

Below are the latest news stories about OKYO PHARMA LTD that investors may wish to consider to help them evaluate OKYO as an investment opportunity.

A OKYO Pharma Limited (LON:OKYO) insider increased their holdings last year

Looking at OKYO Pharma Limited's ( LON:OKYO ) insider transactions over the last year, we can see that insiders were...

Yahoo | December 30, 2022

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its interim results for the six months ended 30 September 2022. Clinical Updates: OK-101 During the past six months the Group’s primary focus has been centered on accomplishing the filing of the investigati

Yahoo | December 30, 2022

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in the first quarter 2023- LONDON and NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market,

Yahoo | December 22, 2022

OKYO to Participate at Biotech Showcase

LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, announced today that the Company is participating in the Biotech Showcase in San Francisco, California from January 9-11, 2023 and will be hosting institutional investor and partnering meetings both at th

Yahoo | December 21, 2022

OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces, that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a secondary public offering of its American Depositary Shares ("ADSs"), each of which

Yahoo | December 6, 2022

Read More 'OKYO' Stories Here

OKYO Price Returns

1-mo 21.35%
3-mo -2.63%
6-mo 6.73%
1-year N/A
3-year N/A
5-year N/A
YTD 16.23%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5697 seconds.